Adimab
Adimab is a company focused on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience, and pain.
6
Funding Rounds
$39.1m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| Er*** An****** |
|
- | |
| Ti***** Ge******* | - | - | - |
| K. Da** Wi***** |
|
- |
| Name | Phone | Social networks | |
|---|---|---|---|
| Ti***** Ge******* | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Adimab has raised a total of $39.08m in funding over 6 rounds.
Key Insights:
- Adimab Series F round: $13.8m
- Adimab funding round, December 2010: $4m
- Adimab Series D round: $8.2m
- Adimab Series C round: $4m
- Adimab Series B round: $3.18m
- Adimab Series A round: $5.9m
Adimab Series F round
$13.8m
Adimab funding round, December 2010
$4m
Adimab Series D round
$8.2m
Adimab Series C round
$4m
Adimab Series B round
$3.18m
Adimab Series A round
$5.9m
Industries
Adimab is active in the following industries: